Perspectives gained from large-scale thrombolytic comparative trials
Why the study?
Does an accelerated regimen of t-PA with intravenous heparin improve outcomes compared to other thrombolytic strategies in patients with acute myocardial infarction?
Population
Patients with acute myocardial infarction from four large-scale thrombolytic comparative trials
Comparison
Accelerated regimen of tissue plasminogen… vs Other thrombolytic strategies from earlier trials
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Affirms early patency as key to AMI survival; leaves open optimal regimens versus contemporary PCI.
Structured PICO
Does an accelerated regimen of t-PA with intravenous heparin improve outcomes compared to other thrombolytic strategies in patients with acute myocardial infarction?
P
Population
Patients with acute myocardial infarction from four large-scale thrombolytic comparative trials (GISSI-2 International, ISIS-3, GUSTO, and INJECT)
I
Intervention
Accelerated regimen of tissue plasminogen activator (t-PA) with intravenous heparin
C
Comparator
Other thrombolytic strategies from earlier trials (e.g., GISSI-2 International and ISIS-3)
This review highlights the superiority of accelerated t-PA with intravenous heparin in acute myocardial infarction and emphasizes early coronary patency as a key determinant of survival.
Cite This Study
Paul W. Armstrong (1996) studied this question.